Inactive Instrument

News Sevion Therapeutics Inc OTC Bulletin Board

Equities

US81834Q1040

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ
Mar. 13	Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates	Apr. 16	AQ
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	Mar. 13	CI
Eloxx Pharmaceuticals : Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases	Mar. 13	PU
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	Mar. 13	MT
Eloxx Pharmaceuticals, Inc. Enters into the Fifth Amendment to the Loan and Security Agreement	Jan. 09	CI
Eloxx Pharmaceuticals, Inc. Announces Resignation of Tomer Kariv from the Board	Dec. 28	CI
Eloxx Pharmaceuticals, Inc. and Zikani Therapeutics, Inc. Enter into the Fourth Amendment to the Loan and Security Agreement	Dec. 15	CI
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update	Nov. 13	AQ
Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Oppenheimer Adjusts Eloxx Pharmaceuticals Price Target to $30 From $60, Maintains Outperform Rating	Nov. 02	MT
Eloxx Pharmaceuticals, Inc.(NasdaqCM:ELOX) dropped from S&P TMI Index	23-10-18	CI
Eloxx Pharmaceuticals, Inc.(OTCPK:ELOX) dropped from NASDAQ Composite Index	23-10-13	CI
Eloxx Pharmaceuticals : October 2023 Investor Presentation	23-10-10	PU
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction	23-10-10	AQ
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria	23-10-09	AQ
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	23-09-19	AQ
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	23-09-18	AQ
Eloxx Pharmaceuticals, Inc. Announces Resignation of Vijay Modur as Head of Research and Development	23-09-15	CI
Oppenheimer Raises Eloxx Pharmaceuticals Price Target to $60 From $55, Maintains Outperform Rating	23-09-14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Sevion Therapeutics Inc OTC Bulletin Board

Equities

US81834Q1040

Summary

Filters